MediWound Advances ESCAREX Program Towards Commercialization
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 32 minutes ago
0mins
Source: Yahoo Finance
- New Contract Support: MediWound Ltd has signed a 10-year contract with BARDA valued at up to $197 million, aimed at supporting NexoBrid's strategic role in mass casualty burn response, thereby enhancing the company's position in the emergency medical market.
- Revenue Guidance Confirmation: The company reaffirmed its revenue guidance for 2026 at $24 million to $26 million, with expected support from government-related development services, demonstrating confidence in future revenue streams.
- Increased R&D Spending: R&D expenses rose from $2.9 million to $5.2 million in Q1 2026, reflecting ongoing investment in the ESCAREX study, although this resulted in an operating loss of $8 million, indicating short-term financial pressure.
- Market Potential Expansion: The market potential for Escorex is validated by an industry consensus document, with peak sales projections reaching $831 million from venous leg ulcers and diabetic foot ulcers, indicating a positive commercial outlook in the chronic wound care sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDWD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDWD
Wall Street analysts forecast MDWD stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 16.680
Low
25.00
Averages
30.00
High
36.00
Current: 16.680
Low
25.00
Averages
30.00
High
36.00
About MDWD
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MediWound Advances ESCAREX Program Towards Commercialization
- New Contract Support: MediWound Ltd has signed a 10-year contract with BARDA valued at up to $197 million, aimed at supporting NexoBrid's strategic role in mass casualty burn response, thereby enhancing the company's position in the emergency medical market.
- Revenue Guidance Confirmation: The company reaffirmed its revenue guidance for 2026 at $24 million to $26 million, with expected support from government-related development services, demonstrating confidence in future revenue streams.
- Increased R&D Spending: R&D expenses rose from $2.9 million to $5.2 million in Q1 2026, reflecting ongoing investment in the ESCAREX study, although this resulted in an operating loss of $8 million, indicating short-term financial pressure.
- Market Potential Expansion: The market potential for Escorex is validated by an industry consensus document, with peak sales projections reaching $831 million from venous leg ulcers and diabetic foot ulcers, indicating a positive commercial outlook in the chronic wound care sector.
See More
Mediwound Shares Enter Oversold Territory
- Oversold Signal: Mediwound Ltd. (Ticker: MDWD) saw its RSI drop to 26.3 on Wednesday, indicating the stock has entered oversold territory, suggesting that the recent heavy selling pressure may be waning, thus providing potential buying opportunities for investors.
- Price Fluctuation: MDWD's stock price hit a low of $14.14 during trading, with the current trading price at $14.33, reflecting a 52-week low of $14.14 and a high of $22.505, indicating significant market volatility.
- Market Comparison: In contrast, the S&P 500 ETF (SPY) has an RSI of 74.2, highlighting MDWD's oversold condition, which may attract investors looking for low-entry opportunities in the market.
- Investor Sentiment: Despite the current low stock price, investors may view this as a favorable entry point, especially as the RSI indicates oversold conditions, potentially leading to increased buying activity.
See More
MediWound Q1 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: MediWound reported a Q1 GAAP EPS of -$0.23, surpassing expectations by $0.42, indicating resilience in profitability despite overall revenue decline.
- Significant Revenue Drop: The company’s Q1 revenue of $1.48M fell 62.6% year-over-year and missed expectations, primarily due to the timing of BARDA-related revenues and delayed shipments from regional conflicts, highlighting external challenges impacting operations.
- Full-Year Guidance Reaffirmed: MediWound reaffirmed its 2026 revenue guidance of $24 million to $26 million, with anticipated revenue from government-related development services in the second half of 2026, reflecting confidence in future growth prospects.
- Clinical Program Expansion: The company showcased its expansion plans for the EscharEx clinical programs at the European Wound Management Association (EWMA) 2026, demonstrating ongoing investment and strategic positioning in innovative treatment solutions.
See More
MediWound to Announce Q1 Earnings on May 27
- Earnings Announcement: MediWound (MDWD) is set to release its Q1 2023 earnings on May 27 before market open, with a consensus EPS estimate of -$0.66, reflecting a staggering 842.9% year-over-year decline, indicating significant profitability challenges ahead.
- Revenue Expectations: The anticipated revenue for Q1 stands at $3.37 million, representing a 99.9% year-over-year drop, which highlights major hurdles in market competition and product sales, potentially undermining investor confidence.
- Historical Performance Review: Over the past two years, MediWound has only surpassed EPS estimates 38% of the time and revenue estimates 63% of the time, showcasing uncertainty in the company's earnings forecasts that could lead to stock price volatility.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and two downward adjustments, while revenue estimates experienced two upward and two downward revisions, indicating a divergence in analyst outlooks on the company's future performance that may impact investor decisions.
See More
U.S. Expert Consensus Supports MediWound's Chronic Wound Treatment Strategy
- Consensus Redefines Debridement: The U.S. multidisciplinary expert panel's consensus redefines debridement as a biologically active intervention that drives healing by reducing biofilm and bacterial burden, providing theoretical support for MediWound's EscharEx® and potentially enhancing its application in the chronic wound care market.
- Importance of Early Treatment: The consensus advocates for prioritizing effective, less invasive treatment methods when appropriate, which not only improves patient treatment experiences but may also reduce healthcare costs, thereby strengthening EscharEx®'s competitive position as a first-line debridement therapy.
- Clinical Research Support: EscharEx® has demonstrated good safety and efficacy in multiple Phase II clinical studies, enabling rapid removal of non-viable tissue and promoting granulation, laying the groundwork for its application in the upcoming Phase III VALUE trial targeting venous leg ulcers, indicating significant market potential.
- Global Market Opportunity: MediWound's innovative EscharEx® therapy for chronic wounds, which combines multiple therapeutic actions, is expected to meet the growing global demand for advanced debridement solutions, further solidifying the company's leadership position in the biotherapeutics field.
See More
MediWound Reports $197 Million BARDA Contract Award to Vericel for NexoBrid
- Significant Contract Value: Vericel has been awarded a ten-year contract by BARDA valued at up to $197 million, with a base contract of $35 million that includes approximately $10 million for initial NexoBrid procurement over the next 12 months, indicating strong demand and market potential for the product.
- Strategic Inventory Management: The contract includes the establishment and maintenance of a Vendor Managed Inventory (VMI) system, which will optimize the supply chain management of NexoBrid, ensuring rapid response in emergencies and enhancing the company's competitiveness in the medical emergency sector.
- Manufacturing Capacity Enhancement: The contract also involves plans for the design and validation of a U.S.-based manufacturing facility, which will not only reduce production costs but also enhance Vericel's production capabilities in the U.S. market, further driving NexoBrid's market penetration.
- New Formulation Development: Vericel will develop a next-generation formulation of NexoBrid and explore additional indications for blast trauma treatment, which is expected to broaden the product's applicability and strengthen the company's strategic position in the biopharmaceutical market.
See More
MediWound Advances ESCAREX Program Towards Commercialization
- New Contract Support: MediWound Ltd has signed a 10-year contract with BARDA valued at up to $197 million, aimed at supporting NexoBrid's strategic role in mass casualty burn response, thereby enhancing the company's position in the emergency medical market.
- Revenue Guidance Confirmation: The company reaffirmed its revenue guidance for 2026 at $24 million to $26 million, with expected support from government-related development services, demonstrating confidence in future revenue streams.
- Increased R&D Spending: R&D expenses rose from $2.9 million to $5.2 million in Q1 2026, reflecting ongoing investment in the ESCAREX study, although this resulted in an operating loss of $8 million, indicating short-term financial pressure.
- Market Potential Expansion: The market potential for Escorex is validated by an industry consensus document, with peak sales projections reaching $831 million from venous leg ulcers and diabetic foot ulcers, indicating a positive commercial outlook in the chronic wound care sector.
See More
Mediwound Shares Enter Oversold Territory
- Oversold Signal: Mediwound Ltd. (Ticker: MDWD) saw its RSI drop to 26.3 on Wednesday, indicating the stock has entered oversold territory, suggesting that the recent heavy selling pressure may be waning, thus providing potential buying opportunities for investors.
- Price Fluctuation: MDWD's stock price hit a low of $14.14 during trading, with the current trading price at $14.33, reflecting a 52-week low of $14.14 and a high of $22.505, indicating significant market volatility.
- Market Comparison: In contrast, the S&P 500 ETF (SPY) has an RSI of 74.2, highlighting MDWD's oversold condition, which may attract investors looking for low-entry opportunities in the market.
- Investor Sentiment: Despite the current low stock price, investors may view this as a favorable entry point, especially as the RSI indicates oversold conditions, potentially leading to increased buying activity.
See More
MediWound Q1 Earnings Beat Expectations Despite Revenue Decline
- Earnings Beat: MediWound reported a Q1 GAAP EPS of -$0.23, surpassing expectations by $0.42, indicating resilience in profitability despite overall revenue decline.
- Significant Revenue Drop: The company’s Q1 revenue of $1.48M fell 62.6% year-over-year and missed expectations, primarily due to the timing of BARDA-related revenues and delayed shipments from regional conflicts, highlighting external challenges impacting operations.
- Full-Year Guidance Reaffirmed: MediWound reaffirmed its 2026 revenue guidance of $24 million to $26 million, with anticipated revenue from government-related development services in the second half of 2026, reflecting confidence in future growth prospects.
- Clinical Program Expansion: The company showcased its expansion plans for the EscharEx clinical programs at the European Wound Management Association (EWMA) 2026, demonstrating ongoing investment and strategic positioning in innovative treatment solutions.
See More
MediWound to Announce Q1 Earnings on May 27
- Earnings Announcement: MediWound (MDWD) is set to release its Q1 2023 earnings on May 27 before market open, with a consensus EPS estimate of -$0.66, reflecting a staggering 842.9% year-over-year decline, indicating significant profitability challenges ahead.
- Revenue Expectations: The anticipated revenue for Q1 stands at $3.37 million, representing a 99.9% year-over-year drop, which highlights major hurdles in market competition and product sales, potentially undermining investor confidence.
- Historical Performance Review: Over the past two years, MediWound has only surpassed EPS estimates 38% of the time and revenue estimates 63% of the time, showcasing uncertainty in the company's earnings forecasts that could lead to stock price volatility.
- Estimate Revision Trends: In the last three months, EPS estimates have seen one upward revision and two downward adjustments, while revenue estimates experienced two upward and two downward revisions, indicating a divergence in analyst outlooks on the company's future performance that may impact investor decisions.
See More
U.S. Expert Consensus Supports MediWound's Chronic Wound Treatment Strategy
- Consensus Redefines Debridement: The U.S. multidisciplinary expert panel's consensus redefines debridement as a biologically active intervention that drives healing by reducing biofilm and bacterial burden, providing theoretical support for MediWound's EscharEx® and potentially enhancing its application in the chronic wound care market.
- Importance of Early Treatment: The consensus advocates for prioritizing effective, less invasive treatment methods when appropriate, which not only improves patient treatment experiences but may also reduce healthcare costs, thereby strengthening EscharEx®'s competitive position as a first-line debridement therapy.
- Clinical Research Support: EscharEx® has demonstrated good safety and efficacy in multiple Phase II clinical studies, enabling rapid removal of non-viable tissue and promoting granulation, laying the groundwork for its application in the upcoming Phase III VALUE trial targeting venous leg ulcers, indicating significant market potential.
- Global Market Opportunity: MediWound's innovative EscharEx® therapy for chronic wounds, which combines multiple therapeutic actions, is expected to meet the growing global demand for advanced debridement solutions, further solidifying the company's leadership position in the biotherapeutics field.
See More
MediWound Reports $197 Million BARDA Contract Award to Vericel for NexoBrid
- Significant Contract Value: Vericel has been awarded a ten-year contract by BARDA valued at up to $197 million, with a base contract of $35 million that includes approximately $10 million for initial NexoBrid procurement over the next 12 months, indicating strong demand and market potential for the product.
- Strategic Inventory Management: The contract includes the establishment and maintenance of a Vendor Managed Inventory (VMI) system, which will optimize the supply chain management of NexoBrid, ensuring rapid response in emergencies and enhancing the company's competitiveness in the medical emergency sector.
- Manufacturing Capacity Enhancement: The contract also involves plans for the design and validation of a U.S.-based manufacturing facility, which will not only reduce production costs but also enhance Vericel's production capabilities in the U.S. market, further driving NexoBrid's market penetration.
- New Formulation Development: Vericel will develop a next-generation formulation of NexoBrid and explore additional indications for blast trauma treatment, which is expected to broaden the product's applicability and strengthen the company's strategic position in the biopharmaceutical market.
See More
